Chronic Myeloid Leukemia (CML)
all indicationsAlso known as: Leukemia, Chronic Myeloid / Chronic Myeloid Leukemia (CML) / Chronic Myeloid Leukaemia / Chronic myeloid leukemia / Myeloid leukemia, chronic / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / CML / Chronic myelogenous leukaemia / Chronic myelocytic leukaemia / Leukemia myelocytic chronic / Chronic myelogenous leukemia / Leukaemia myelocytic chronic / Chronic granulocytic leukemia / Leukaemias chronic myeloid / Chronic myelocytic leukemia / Chronic granulocytic leukaemia / Myeloid leukaemia, chronic
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB00531 | Cyclophosphamide | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. [PubChem] |
| DB01254 | Dasatinib | Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR. |
| DB00619 | Imatinib | Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells. |